FHTX stock forecast, quote, news & analysis
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system... Show more
Why Foghorn Therapeutics (FHTX) Stock Is Up +21% in the Last 30 Days
Key Takeaways
- Foghorn Therapeutics (FHTX) surged approximately 21% over the past 30 days, climbing from $4.22 on June 26 to $5.13 as of July 28, 2026.
- The rally was fueled by mounting anticipation ahead of a mid-2026 dose-expansion decision for lead candidate FHD-909, partnered with Eli Lilly (LLY), in SMARCA4-mutated non-small cell lung cancer.
- Over the last quarter, FHTX shares were roughly flat, masking a sharp sell-off from $5.17 in late April to lows near $3.54 in early June, followed by a robust recovery.
- Multiple analysts reiterated Buy ratings with price targets ranging from $9 to $14 following compelling AACR 2026 preclinical data presentations in April.
- The company maintains a strong cash position of approximately $184 million as of March 31, 2026, with runway extending into the first half of 2028.
- Upcoming catalysts include the FHD-909 Phase 1 expansion decision, second-quarter 2026 earnings expected in early August, and IND-enabling study progress across the degrader pipeline.
Foghorn Therapeutics (FHTX) Company Overview and Market Position
Foghorn Therapeutics is a clinical-stage biotechnology company pioneering a new class of medicines that target genetically determined dependencies within the chromatin regulatory system. Using its proprietary Gene Traffic Control platform, Foghorn systematically identifies and validates drug targets involved in gene expression — a biological process implicated in up to 50% of all tumors. The company's lead candidate, FHD-909 (LY4050784), is a first-in-class oral SMARCA2 selective inhibitor being developed in a 50/50 U.S. co-development and co-commercialization partnership with Eli Lilly (LLY). Beyond FHD-909, Foghorn is advancing a wholly owned pipeline of selective protein degraders targeting CBP, EP300, and ARID1B across ER+ breast cancer, multiple myeloma, diffuse large B-cell lymphoma, and other solid tumors. Investors closely follow FHTX for its high-risk, high-reward oncology pipeline and its strategic collaboration with one of the world's largest pharmaceutical companies.
Foghorn Therapeutics (FHTX) Stock Price Performance: Last 30 Days vs. Quarter
Over the past 30 days, FHTX delivered a gain of approximately 21%, rising from a closing price of $4.22 on June 26, 2026, to $5.13 on July 28. The move was marked by a significant volume spike on June 26 — when over 1.2 million shares traded — and a powerful rally in the first week of July that took the stock as high as $6.17 on July 8 before a partial pullback set in. The 30-day advance reflects renewed investor conviction after a prolonged period of weakness.
Zooming out to the last quarter, however, FHTX shares were essentially flat. The stock closed at $5.17 on April 28, meaning the quarterly move registers a marginal decline of approximately 0.9%. But that near-flat return conceals substantial intra-quarter volatility: shares tumbled from roughly $5.17 in late April to a trough of $3.54 in early June, driven by sector-wide pressure on pre-revenue biotechnology companies. The subsequent recovery erased those losses and brought the stock back to its starting point, underscoring the high-beta nature of the name.
What Drove FHTX Stock Price in the Last 30 Days
The 21% rally over the past 30 days was primarily driven by growing investor anticipation around the upcoming FHD-909 Phase 1 dose-expansion decision, which Eli Lilly (LLY) is expected to make in mid-2026. At the Goldman Sachs 47th Annual Global Healthcare Conference in June, Foghorn management confirmed that FHD-909 is nearing this key inflection point, and analysts at Stifel and H.C. Wainwright previously flagged the decision as a major potential value driver.
Additional support came from the lingering halo of positive preclinical data presented at the AACR Annual Meeting in April 2026, where FHD-909 in combination with an anti-PD-1 antibody demonstrated complete and durable tumor regression along with anti-tumor immune memory in syngeneic mouse models. These data reinforced both the mechanistic rationale and the commercial opportunity for the program. Institutional activity also provided a tailwind, with Candriam S.C.A. disclosing a new $1.5 million position in the first quarter and overall institutional ownership standing at 61.55% of the float.
On the sentiment side, the consensus analyst rating on FHTX remains a Strong Buy, with an average 12-month price target of approximately $11.44 — roughly 120% above current levels — according to data from S&P Global and MarketBeat. The wide gap between the trading price and analyst targets contributed to buying interest among speculative investors betting on pipeline catalysts materializing in the second half of 2026.
What Drove FHTX Stock Performance Over the Last Quarter
The quarterly performance of FHTX was defined by a pronounced V-shaped pattern. Between late April and early June, the stock lost roughly 31% of its value, tumbling from $5.17 to $3.54 as broader market sentiment turned against early-stage, pre-revenue biotech names. Fears around elevated interest rates, reduced risk appetite, and a rotation away from speculative growth assets weighed heavily on the sector. Foghorn's Q1 2026 earnings, released on May 7, showed a narrower-than-expected net loss of $0.29 per share and a cash runway into the first half of 2028, but were not enough to halt the slide.
The recovery that began in mid-June and accelerated into July was driven by a convergence of positive pipeline momentum, the approaching FHD-909 expansion decision, and bargain hunting after shares traded well below analyst price targets. The company's appearances at multiple investor conferences in May and June — including H.C. Wainwright, Stifel, TD Cowen, and Goldman Sachs — kept the investment narrative in focus and allowed management to reinforce timelines for IND-enabling studies across the CBP, EP300, and ARID1B degrader programs.
Trending AI Robots
In a market environment where timing and data-driven decision-making are increasingly critical, Tickeron's Trending AI Robots page offers a curated view of top-performing AI-powered trading bots. Tickeron hosts hundreds of AI trading bots that execute across thousands of tickers, but only those demonstrating consistent, verifiable performance and strategic relevance appear in this select section. The bots span a wide range of strategies — from short-term momentum plays to longer-horizon swing and trend-following approaches — each with distinct risk profiles and performance metrics. For traders seeking algorithmic insight into stocks like FHTX or the broader biotechnology sector, exploring the Trending AI Robots page can provide an additional layer of quantitative perspective.
FHTX Stock Forecast Drivers: What Investors Should Watch Next
The immediate catalyst for FHTX is the FHD-909 Phase 1 dose-expansion decision by Eli Lilly (LLY), expected in mid-2026. A positive decision would open the door to combination studies in the front-line NSCLC setting, dramatically expanding the program's addressable market. Preliminary Phase 1 monotherapy data may also be disclosed around the same time.
Second-quarter 2026 earnings, anticipated in early August, will provide updates on clinical enrollment progress, financial runway, and milestone timelines for the wholly owned degrader pipeline. Additionally, IND-enabling studies for the Selective CBP degrader (FHT-171) and Selective EP300 degrader programs are expected to advance through 2026, with IND filings anticipated in 2027. Investors should also monitor the Selective ARID1B degrader program as it moves toward in vivo proof-of-concept data. On the macro side, interest rate expectations and risk appetite for pre-revenue biotech names will continue to influence sector-wide valuations and are likely to affect FHTX's trading range.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
FHTX's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for FHTX turned positive on August 07, 2026. Looking at past instances where FHTX's MACD turned positive, the stock continued to rise in of 36 cases over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on August 06, 2026. You may want to consider a long position or call options on FHTX as a result. In of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
FHTX moved above its 50-day moving average on August 04, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where FHTX advanced for three days, in of 281 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FHTX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
FHTX broke above its upper Bollinger Band on August 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for FHTX entered a downward trend on August 07, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. FHTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (20.121). P/E Ratio (0.000) is within average values for comparable stocks, (25.620). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.855). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. P/S Ratio (12.019) is also within normal values, averaging (466.660).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FHTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology